Table 3.
Outcomes for patients who developed secondary B cell lymphoma
| Disease classification | Sex | Agea | Duration of forodesine administration (days) | Duration to development of sBCLb (days) | Treatments for sBCL/response | Outcome |
|---|---|---|---|---|---|---|
| AITL | F | 71 | 447 | 450 | R-DeVIC/CR | Alive with AITL |
| AITL | F | 70 | 171 | 203 | R-CHOP/PD | Died from lymphoma (AITL, sBCL) |
| AITL | F | 76 | 67 | 436 | PSL/unknown | Died from lymphoma (AITL, sBCL) |
| PTCL, NOS | F | 72 | 353 | 281 | PSL/unknown | unknown |
| PTCL, NOS | F | 65 | 505 | 506 | R-COP/PD R-CHOP/PD DEX/PD | Died from lymphoma (PTCL, NOS, sBCL) |
AITL angioimmunoblastic T cell lymphoma; COP rituximab plus cyclophosphamide, vincristine, prednisone; CR complete response; F female; PD progression disease; PSL prednisolone; PTCL peripheral T cell lymphoma; R-CHOP rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone; R-DeVIC rituximab plus dexamethasone, etoposide, ifosfamide, carboplatin; R-DEX dexamethasone; R-GDP rituximab plus gemcitabine, dexamethasone, cisplatin; sBCL secondary B cell lymphoma
aAge at the time of informed consent
bDuration from initial forodesine administration to development of sBCL